Portal de Periódicos da CAPES

The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™)

2013; Elsevier BV; Volume: 32; Issue: 4 Linguagem: Inglês

10.1016/j.healun.2013.01.020

1557-3117

G. Warnecke, Benno Weigmann, Dirk Van Raemdonck, Gilbert Massard, Nicola Santelmo, Pierre‐Emmanuel Falcoz, Anne Olland, Guy Lesèche, Hervé Mal, P. Thomas, Federico Rea, Giuseppe Marulli, Christoph Knosalla, Roland Hetzer, A. Ardehali, Jasleen Kukreja, C. Bermúdez, Javier Moradiellos, A. Varela, K. Dhital, Jayan Nagendran, Kenneth R. McCurry, Axel Haverich,

Organ and Tissue Transplantation Research

grafts were reperfused for 4h.Hemodynamics (PVR), pO 2 /FiO 2 and dynamic compliance (DLC) were compared to lungs without pretreatment (group 1) and sham-controls (Sham).To prove and localize the Texas-red labelled MSCs in the lung, PCR was performed and cryosections were counter-stained with WGA and DAPI.Intraalveolar edema was determined sterologically.Statistics comprised ANOVA with repeated measurements.Results: PVR and DLC were superior in endobronchially pretreated MSC lungs as compared to endovascular MSC application and lungs without pretreatment.Oxygenation was worst after endovascular pretreatment.Stereology revealed low intrapulmonary edema in all groups (p40.05),successful MSC application was proven by PCR.MSC were localized in alveola and capillaries.Conclusions: Intrapulmonary deposition of BM-MSC in NHBD is feasible, but only endobronchial application optimizes DLC and PVR postoperatively.Due to immunomodulatory and paracrine effects on epithelial restitution, autologous-BM-MSC-based donor pretreatment for prevention or attenuation of limiting BOS is very promising in LTx.